ClinicalTrials.gg
RecruitingNCT05838729Updated Sep 17, 2025

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

A Phase 1/2 interventional study of RiMO-301 in Head Neck Cancer and Intratumoral Injection, sponsored by Coordination Pharmaceuticals, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Coordination Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,317 studies in Head and Neck Neoplasms with a site in United States — 187 open to participants now, 283 under way, 15 of them phase 3. Head and Neck Neoplasms · United States.

Planned enrollment
799th of 1,073
16 · median 36
Started
2023
with 54 others
Phase 1/2
117 of 1,317
22 open now
Primary completion
2026-09
later than 51 of 282 live
Registered
1,143rd of 1,317
by date

Among the 1,317 studies in Head and Neck Neoplasms with a site in United States, this one is the 799th largest by planned enrollment of the 1,073 interventional ones that give a count, is one of 55 that started in 2023, is one of 117 in phase 1/2, reaches primary completion later than 51 of the 282 other live ones, and was the 1,143rd registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

187 of the 1,317 studies in Head and Neck Neoplasms with a site in United States are open now. Recruiting first, the newest first:

182 more — sign in →

All 187 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,317 studies in Head and Neck Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.

Read the detailed description

Primary Objectives:

  • To determine the tolerability of RiMO-301 with hypofractionated X-ray radiotherapy and a PD-1 inhibitor (pembrolizumab or nivolumab) in patients with unresectable, recurrent or metastatic head-neck cancer
  • To determine the efficacy of RiMO-301 with hypofractionated X-ray radiotherapy and a PD-1 inhibitor (pembrolizumab or nivolumab)

Secondary Objectives:

  • To evaluate progression-free survival for up to 12 months
  • To determine overall survival for up to 24 months
  • To assess patient quality of life

The target population is patients with unresectable, recurrent or metastatic head-neck cancer which is clinically accessible to intratumoral injection.

03

Conditions studied

  • Head Neck Cancer
  • Intratumoral Injection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of head-neck cancer that requires palliative radiotherapy
  • Patients with unresectable, recurrent or HNSCC, regardless if the patients have progressed on or are intolerant to platinum-based chemotherapy prior to study enrollment or if the patients are receiving pembrolizumab in the :

    • receiving a inhibitor (pembrolizumab or nivolumab) as a standard of care, or
    • suitable to receive a PD-1 inhibitor (pembrolizumab or nivolumab) as a standard of care in the discretion of the treating physician or Principal Investigator
  • Must have at least 1 target lesion that is clinically accessible to RiMO-301 injection and amenable to receive RT regimens specified in this protocol
  • The selected target lesions must be measurable on cross-sectional imaging and repeated measurements at the same location should be achievable
  • Target tumor not in the previously irradiated field or in the field irradiated at least six months prior to RiMO-301 injection and with no complications from the prior radiation course
  • RiMO-301 injection to multiple lesions (≤ 5 in total) in a single patient is allowed as long as the total tumor volume does not exceed 250 cm3
  • Patient must have recovered from acute toxic effects (≤ grade 1 CTCAEv5) of previous cancer treatments prior to enrollment
  • Have adequate bone marrow reserve and adequate liver function
  • Have a of at least 12 weeks
  • score of 0-2
  • Age 18 years or older

Exclusion criteria

Exclusion Criteria:

  • Have signs or symptoms of end organ failure, major chronic illnesses other than cancer, or any severe concomitant conditions
  • Symptomatic central nervous system and/or carcinomatous meningitis
  • Active disease that has required systemic treatment in the past 2 years
  • Ongoing infection at or near the incident lesion
  • Major surgery over the target area (excluding placement of vascular access) ≤21 days from beginning of the study drug or minor surgical procedures ≤7 days. No waiting is required following implantable port, enteral feeding tube and catheter placement
  • Has received any approved or anti-neoplastic agent or immunotherapy other than inhibitors (pembrolizumab or nivolumab) within 4 weeks prior to RiMO-301 injection
  • Patients with lesions which have significant blood vessel involvement (such as carotid artery encasement) or other major structures
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    RiMO-301

    Intratumoral injection of RiMO-301 followed by pembrolizumab or nivolumab followed by hypofractionated radiation

    Drug: RiMO-301

Interventions

  • DrugMOF Compound RiMO-301Studies of MOF Compound RiMO-301MOF Compound RiMO-301 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A single dose of RiMO-301 will be administered via an intratumoral injection. PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity. Patients will receive hypofractionated radiation in 5 fractions.

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Determination of Recommended Dose

    • The dose limiting toxicities of RiMO-301 with hypofractionated X-ray radiotherapy and a PD-1 inhibitor, as assessed by CTCAEv5, will not be observed in 33% or more patients

    Time frame: 6 weeks

  2. Evaluation of Anti-Tumor Response

    • To determine the objective response rate: complete or partial response, as defined by RECIST and itRECIST

    Time frame: 12 months

Secondary outcomes

  1. Evaluation of Progression-Free Survival

    Time from enrollment to local-regional recurrence, local-regional progression, distant progression or death from any cause, whichever occurs first

    Time frame: 12 months

  2. Evaluation of Overall Survival

    Time from enrollment to death from any cause

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Sep 2026, 41 months after the start.

Of 51 industry-sponsored phase 1/2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's planned 41 months is below that.

Counting every sponsor, half of 90 studies reached it within 54 months; a quarter within 41 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2023
First posted
May 1, 2023
StartActual
Apr 3, 2023
Primary completionEst.
Sep 2026
CompletionEst.
Dec 2026
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05838729
Lead sponsor
Coordination Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
May 1, 2023
Start date
Apr 3, 2023
Primary completion
Sep 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 17, 2025

Study contacts

Ze-Qi Xu
Contact
zq@coordinationpharma.com
630-415-5601
Lawrence Feldman, MD
principal investigator · University of Illinois at Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MOF Compound RiMO-301

Start the discussion